Skip to content
Logo
  • Home
  • FeNO
    • What is FeNO?
    • FeNO in asthma
    • Benefits of FeNO use
    • Measuring FeNO with the NObreath®
  • NObreath®
    • What is the NObreath®?
    • Already own a NObreath®
    • How to use the NObreath®
    • Consumables
    • Where to buy?
    • Literature
  • Forum
  • News
  • Medical Advisory Board
  • Software
  • Support
    • Educational Portal
    • FAQs
    • Literature
    • How to videos
    • Coronavirus and FeNO breath testing
    • Optimising Asthma Care using FeNO
  • Contact
  • English
    • English
    • United States
Sep 17
NObreath banner

Bedfont announces launch of 2nd Generation NObreath at ERS 2018, Paris

Bedfont announces launch of 2nd generation NObreath at ERS 2018, Paris

Bedfont Scientific Ltd. launches their new FeNO monitor exclusively at the world’s largest European Respiratory Society Congress.
Medical device manufacturer, Bedfont, specialising in breath analysis for 40+ years, have announced a new and improved 2nd generation NObreath. The monitor will be launched at ERS, the world’s largest European Respiratory Society Congress, taking place September 15-19th in Paris.

The FeNO monitor will launch after the recent publication of NICE guidance on Asthma: diagnosis, monitoring and chronic asthma management. Put in place to improve asthma care, including the NObreath FeNO monitor from Bedfont as a recommended device1,2.

To celebrate the exclusive launch, the second-generation family business will also be holding a competition at their stand where delegates will have the chance to be entered into a prize draw to win a new NObreath.

Jason Smith, Managing Director, comments, “As a breath analysis medical device manufacturer who exports globally, ERS is a key congress for us to reconnect with our customers from around the world. We are thrilled to be launching the 2nd generation NObreath exclusively at ERS this year as we feel it would be quite symbolic; this launch will bring the product full circle, as the very first NObreath was too launched at an ERS Congress 11 years ago. We’re excited to show our customers what’s in store for the advancement of respiratory care.”

-ends-

REFERENCES
1. Asthma: diagnosis, monitoring and chronic asthma management | Guidance and guidelines | NICE [Internet]. Nice.org.uk. 2018 [cited 24 April 2018]. Available from: https://www.nice.org.uk/guidance/ng80

2. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath | Guidance and guidelines | NICE [Internet]. Nice.org.uk. 2014 [cited 24 April 2018]. Available from: https://www.nice.org.uk/guidance/dg12

Media release date: 12th September 2018

Leave a reply Cancel reply

Your email address will not be published. Required fields are marked *

Contact Details

Bedfont® Scientific Ltd
Station Road, Harrietsham, Maidstone
Kent, ME17 1JA, England

Tel: +44(0)1622 851122
Email: ask@bedfont.com

Products

NObreath®

Smokerlyzer®

Gastrolyzer®

ToxCO®

Medi-Gas Check

Accreditations

ISO 13485:2016

Bedfont EC REP - Emergo

Useful Links

What is FeNO?

FeNOchart™

What is the NObreath®?

Resources

FAQs

Contact Us


References



White Bedfont text logo

© 1976-2025 Bedfont® Scientific Ltd., all rights reserved | Incorporated in England and Wales under registered number: 1289798

Legal Stuff | Privacy Notice | Help Centre